Reduced recurrence of low-risk non-muscle-invasive bladder cancer is associated with low urine-specific gravity.
bladder cancer
fluid intake
hydration
urinary marker
urine-specific gravity
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
24
01
2020
accepted:
13
07
2020
pubmed:
15
8
2020
medline:
28
4
2021
entrez:
15
8
2020
Statut:
ppublish
Résumé
To investigate the association between urine-specific gravity and oncological outcomes in patients with non-muscle-invasive bladder cancer. We identified 433 primary non-muscle-invasive bladder cancer patients who underwent transurethral resection between 2002 and 2016. The association between urine-specific gravity and tumor recurrence was statistically evaluated. A total of 211 (48.7%) patients received adjuvant bacillus Calmette-Guérin therapy. During the median follow-up period of 60 months, 155 (35.8%) patients experienced at least one tumor recurrence. Of them all, 95 (21.9%) and 338 (78.1%) patients had high (>1.020) and low (≤1.020) urine-specific gravity, respectively. The Kaplan-Meier curve suggested that recurrence-free survival was significantly lower in patients with a high urine-specific gravity; however, the multivariate analysis failed to show that urine-specific gravity is significantly associated with tumor recurrence. In 222 (51.3%) patients who had not received bacillus Calmette-Guérin therapy, the Kaplan-Meier curve also suggested that recurrence-free survival was significantly lower in patients with a high urine-specific gravity. Multivariate analysis showed that age >70 years (hazard ratio 1.69, P = 0.02), grade 3 tumor (hazard ratio 1.81, P = 0.03) and high urine-specific gravity (hazard ratio 1.87, P < 0.01) were independent risk factors for tumor recurrence. High urine-specific gravity is an independent risk factor for tumor recurrence in non-muscle-invasive bladder cancer patients who have not received bacillus Calmette-Guérin therapy. Our results suggest that hydration status might have some clinical impacts on bladder tumor recurrence.
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019-1023Informations de copyright
© 2020 The Japanese Urological Association.
Références
Babjuk M, Burger M, Compérat EM et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur. Urol. 2019; 76: 639-57.
Chang SS, Boorjian SA, Chou R et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J. Urol. 2016; 196: 1021-9.
van Rhijn BW, Burger M, Lotan Y et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 2009;56: 430-42.
Michaud DS, Spiegelman D, Clinton SK et al. Fluid intake and the risk of bladder cancer in men. N. Engl. J. Med. 1999; 340: 1390-7.
Hemelt M, Hu Z, Zhong Z et al. Fluid intake and the risk of bladder cancer: results from the South and East China case-control study on bladder cancer. Int. J. Cancer 2010; 127: 638-45.
Zhou J, Smith S, Giovannucci E et al. Reexamination of total fluid intake and bladder cancer in the health professionals follow-up study cohort. Am. J. Epidemiol. 2012; 175: 696-705.
Villanueva CM, Cantor KP, King WD et al. Total and specific fluid consumption as determinants of bladder cancer risk. Int J. Cancer. 2006; 118: 2040-7.
Radosavljević V, Janković S, Marinković J, Djokić M. Fluid intake and bladder cancer. A case control study. Neoplasma 2003; 50: 234-8.
Donat SM, Bayuga S, Herr HW et al. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J. Urol. 2003; 170: 1777-80.
Armstrong LE, Soto JA, Hacker FT Jr et al. Urinary indices during dehydration, exercise, and rehydration. Int. J. Sport. Nutr. 1998; 8: 345-55.
Epstein JI, Amin MB, Reuter VR et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 1998; 22: 1435-48.
Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer, 7th edn. Wiley-Blackwell, Hoboken, 2009.
Matsumoto K, Gondo T, Hayakawa N et al. The role of single instillation chemotherapy in patients who receive subsequent bacillus Calmette-Guérin: A retrospective single centre study, and systematic review of the literature. Can. Urol. Assoc. J. 2015; 9: 411.
Niwa N, Matsumoto K, Hayakawa N et al. Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: a matched-pair analysis. Urol. Oncol. 2015; 33: 386.e15-386.e21.
Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 466-77.
Raman JD, Ng CK, Boorjian SA et al. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int. 2005; 96: 1031-5.
Jochems SHJ, van Osch FHM, Reulen RC et al. Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. Bladder Cancer. 2018; 4: 303-10.
Global Burden of Disease Health Financing Collaborator Network. Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet 2017; 389: 1981-2004.
Braver DJ, Modan M, Chetrit A et al. Drinking, micturition habits, and urine concentration as potential risk factors in urinary bladder cancer. J. Natl. Cancer Inst. 1987; https://doi.org/10.1093/jnci/78.3.437.
Vartolomei MD, Ferro M, Cantiello F et al. Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer. 2018; 16: 445-52.
Niwa N, Matsumoto K, Ide H et al. Prognostic value of pretreatment albumin-to-globulin ratio in patients with non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer. 2018; 16: e655-e661.
Ferro M, Vartolomei MD, Russo GI et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J. Urol. 2019; 37: 507-14.
Chu KF, Rotker K, Ellsworth P. The impact of obesity on benign and malignant urologic conditions. Postgrad. Med. 2013; 125: 53-69.
Chang T, Ravi N, Plegue MA et al. Inadequate hydration, BMI, and obesity among US adults: NHANES 2009-2012. Ann. Fam. Med. 2016; 14: 320-4.
Perrier ET, Damazieres A, Girard N et al. Circadian variation and responsiveness of hydration biomarkers to changes in daily water intake. Eur. J. Appl. Physiol. 2013; 113: 2143-51.
Bottin JH, Lemetais G, Poupin M et al. Equivalence of afternoon spot and 24-h urinary hydration biomarkers in free-living healthy adults. Eur. J. Clin. Nutr. 2016; 70: 904-7.
Fischbach FT. A Manual of laboratory and diagnostic tests, 7th edn. Lippincott Williams & Wilkins, Philadelphia, 2003.
Kavouras SA. Assessing hydration status. Curr. Opin. Clin. Nutr. Metab. Care. 2002; 5: 519-24.
Kutlu M, Guler G. Assessment of hydration status by urinary analysis of elite junior taekwon-do athletes in preparing for competition. J. Sports. Sci. 2006; 24: 869-73.